Candel Therapeutics Stock Gains on Launch of Phase 3 Trial for Lung-Cancer Drug
By Elias Schisgall
Shares of Candel Therapeutics rose after the company said it was initiating a pivotal Phase 3 trial to evaluate a lung-cancer treatment.
Shares were up 8.4% to $11.23 in trading midday Tuesday. The stock has nearly doubled in value this year.
The company said Tuesday that it had engaged the clinical-research organization Parexel International to help execute the trial, which will evaluate aglatimagene besadenovec plus valacyclovir in combination with continued pembrolizumab for patients with metastatic, non-squamous non-small cell lung cancer whose disease has progressed despite treatment with pembrolizumab and platinum-based chemotherapy.
The trial is expected to enroll patients across 150 sites, with a primary endpoint of overall survival and secondary endpoints including safety and quality-of-life assessments, said Candel.
The drug has been granted fast-track designation by the Food and Drug Administration, the biopharmaceutical company said.
"Building on our completed Phase 2 clinical trial, we have refined the target patient population by integrating clinical and biomarker insights to maximize the likelihood of success of the Phase 3 trial," Chief Executive Officer Paul Peter Tak said.
Write to Elias Schisgall at elias.schisgall@wsj.com
(END) Dow Jones Newswires
June 30, 2026 12:11 ET (16:11 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
3 Stocks to Sell and 3 Stocks to Buy in August
These 15 Stocks Destroyed the Most Shareholder Value Over the Past Decade
10 Best Growth Stocks to Buy for the Long Term
One Statistician’s Warning for Retirees About the 4% Rule
United States